Combining drugs to improve cancer treatment by reversing DNA changes
Epigenetic Synergy Between DNMT and EZH1/2 Inhibitors for Therapy in Solid Tumors
This study is looking at a new way to treat solid tumors by using special drugs that change how DNA works in cancer cells, which might make other treatments, like immunotherapy, work better for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Coriell Institute for Medical Research NIH-funded |
| Lab location | 1 site (Camden, United States) |
| Project ID | NIH-10886785 on NIH RePORTER |
What this research studies
This research investigates the use of DNA methyltransferase inhibitors (DNMTi) alongside EZH1/2 inhibitors to enhance cancer treatment, particularly for solid tumors. The approach focuses on reversing abnormal DNA methylation in cancer cells, which can improve the effectiveness of immunotherapy. By blocking certain repressive activities that contribute to treatment resistance, the study aims to uncover new mechanisms that could lead to better patient outcomes. Patients may benefit from a combination therapy that targets both DNA methylation and immune response pathways.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with solid tumors who have not responded adequately to current treatments.
Not a fit: Patients with non-solid tumors or those who have not been diagnosed with cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments that enhance the immune system's ability to fight tumors.
How similar studies have performed: Previous research has shown promising results with similar combinations of epigenetic therapies, indicating potential for success in this novel approach.
Where this research is happening
Camden, United States
- Coriell Institute for Medical Research — Camden, United States (Active)
Researchers
- Principal investigator: Rothbart, Scott — Coriell Institute for Medical Research
- Study coordinator: Rothbart, Scott
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.